EUCTR2014-004072-30-ES进行中（未招募）1 期
A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) previously untreated - SUNINET
Grupo Español de Tumores Neuroendocrinos0 个研究点目标入组 43 人开始时间: 2014年12月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female, 18 years of age or older.
- •2. ECOG performance status 0-1.
- •3. Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of < or = 20% (well and moderately differentiated)
- •4. Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent.
- •5. Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted.
- •6. Documented progression disease by CT scan, MR or Octreoscan in 12 months prior basal visit.
- •7. Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.
- •8. Patient has to be able to swallow the medication.
- •9. Life expectancy greater than 12 weeks.
- •10. The definitions of minimum adequacy for organ function required prior to study entry are as follows.
- •Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ? 2.5 x upper limit of normal (ULN), or AST and ALT ? 5 x ULN if liver function abnormalities are due to underlying malignancy
- •Total serum bilirubin ? 1.5 x ULN
- •Serum albumin ? 3.0 g/dL
- •Absolute neutrophil count (ANC) ? 1500/µL
- •Platelets ?100,000/µL
- •Hemoglobin ? 5,6 mmol/L (9.0 g/dL)
- •Creatinin clearance > 40 mL/min (Cockroft and Gault formula)
- •11. Adequate cardiac function: 12-lead ECG without pathologic findings (clinically significant alterations are allowed) and Echocardiogram / Normal MUGA (LVEF> 50%)
- •12. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
- •13. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •1. Previous treatments with chemotherapy, monoclonal antibodies anti-VEGF, tyrosine kinase inhibitors, mTOR inhibitors, or interferon are not permitted for the advanced disease.
- •2. Prior treatment on another hypoxia-activated prodrug under clinical trial.
- •3. Major surgery, radiation therapy, or systemic therapy within 3 weeks of study randomization except palliative radiotherapy to non-target metastatic lesions.
- •4. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
- •5. Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids taken concurrently or within last 3 months prior to randomization
- •6. Treatment with known inhibitors or inductors of CYP3A4 or that prolong the QT interval in the previous 7 days.
- •7. Prior radiation therapy to >25% of the bone marrow.
- •8. Current treatment on another clinical trial.
- •9. Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months prior to first dose of treatment on study and should be asymptomatic.
- •10. Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- •11. Any of the following within the 12 months prior to starting study treatment:
- •- myocardial infarction,
- •- severe/unstable angina,
- •- coronary/peripheral artery bypass graft,
- •- congestive heart failure class III or IV of the New York Heart Association (NYHA) or patients with clinical history of congestive heart failure clase III or IV of the NYHA, unless an echocardiogram or MUGA in the pevious 3 months to selection shows a LVEF ? 45 %
- •- significant heart valve disease
- •- cerebrovascular accident including transient ischemic attack
- •- pulmonary embolus.
- •12. Ongoing cardiac dysrhythmias of NCI CTCAE grade ? 2, atrial fibrillation of any grade, or QTc interval >450 msec for males or >470 msec for females.
- •13. Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
- •14. Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with hypoxemia or oxigen saturation < 90% after a march of two minutes.
- •15. Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
- •16. Known human immunodeficiency virus infection.
- •17. Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to inclusion.
- •18. Previous allergic reaction to components structurally similar to TH-302 or sunitinib or any of the excipients of drugs.
- •19. Non-healing wound, fistulae, active peptic ulcer or bone fracture.
- •20. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, ex
研究者
相似试验
进行中（未招募）
不适用
A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET).Patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumorsMedDRA version: 17.1Level: LLTClassification code 10068916Term: Pancreatic neuroendocrine tumor metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003924-34-ESGrupo Español de Tumores Neuroendocrinos (GETNE)
进行中（未招募）
1 期
A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell lymphoma, not eligible for high-dose chemotherapy and autologous transplantation [Lenalidomide and DLBCL - NDpatients affected by diffused linfoma with big cellsMedDRA version: 9.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2008-003729-18-ITOSPEDALE S. RAFFAELE38
进行中（未招募）
1 期
Phase II study with Cabozantinib in patients with RET positive NSCLCAdvanced RET-rearranged non-small cell lung cancerMedDRA version: 21.1Level: LLTClassification code 10064049Term: Lung adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002948-88-ITALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA25
进行中（未招募）
1 期
A clinical trial investigating how effective and safe the combination of drugs rituximab and pembrolizumab is at treating patients with Waldenström's Macroglobulinaemia that have not responded to their initial treatment or their disease has come back after being treated.Relapsed and refractory Waldenström's MacroglobulinaemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001767-23-GBniversity College London42
招募中
不适用
A phase II trial examining the safety and preliminary efficacy of repetitive transcranial magnetic stimulation (rTMS) for people living with multiple sclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12622000064707niversity of Tasmania108